HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022
November 28 2022 - 9:00AM
Heart Test Laboratories, Inc. d/b/a
HeartSciences (NASDAQ: HSCS; HSCSW)
(“HeartSciences” or the “Company”), a medical
technology company focused on saving lives by making an ECG (also
known as an EKG) a far more valuable screening tool through the use
of AI, today announced that Andrew Simpson, Chief Executive Officer
of HeartSciences, will be presenting at the 2022 RHK Disruptive
Growth Conference being held December 5-6, 2022 at the offices of
Reed Smith in New York City.
Presentation details are as follows:
Event: |
RHK Capital Disruptive Growth Conference |
Date: |
Monday, December 5, 2022 |
Time: |
1:20 p.m. ET |
About the RHK Capital Disruptive Growth
Conference
The RHK Capital 2022 Disruptive Growth
Conference hosted at Reed Smith, will offer the exclusive
opportunity to discover disruptive and growth companies.
Up to 50 senior management teams will be presenting to an
audience of over 200 institutional investors, accredited investors,
family offices, Wall Street analysts, financial advisors, broker
dealer wealth managers and RHK clients. To receive additional
information, request an invitation or to schedule a one-on-one
meeting, please visit Disrupt-NYC.
About HeartSciences
Heart Test Laboratories, Inc. d/b/a
HeartSciences is a medical technology company focused on applying
innovative AI-based technology to an ECG (also known as an EKG) to
expand and improve an ECG’s clinical usefulness. Millions of ECGs
are performed every week and the Company’s objective is to improve
healthcare by making an ECG a far more valuable cardiac screening
tool, particularly in frontline or point-of-care clinical settings.
HeartSciences’ first product candidate for FDA clearance, the
MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that
is also designed to provide diagnostic information related to
cardiac dysfunction which has traditionally only been available
through the use of cardiac imaging. The MyoVista® also provides
conventional ECG information in the same test. The business model,
which involves the use of the MyoVista® device and consumables for
each test, is expected to be “razor-razorblade” as the electrodes
used with the MyoVista® are proprietary to HeartSciences, and new
electrodes are required for every test performed.For more
information, please visit: https://www.heartsciences.com.
Twitter: @HeartSciences
Safe Harbor StatementThis
announcement contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These forward-looking statements
are made under the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995 and are relating to the
Company's future financial and operating performance. All
statements, other than statements of historical facts, included
herein are "forward-looking statements" including, among other
things, statements about HeartSciences’ beliefs and expectations.
These statements are based on current expectations, assumptions and
uncertainties involving judgments about, among other things, future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company's control. The
expectations reflected in these forward-looking statements involve
significant assumptions, risks and uncertainties, and these
expectations may prove to be incorrect. Investors should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Potential risks and
uncertainties include, but are not limited to, risks discussed in
HeartSciences’ filings with the U.S. Securities and Exchange
Commission at www.sec.gov. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
For Investor and Media Inquiries, please
contact:
Investor Relations:Crescendo Communications, LLCPhone: (212)
671-1021Email: HSCS@crescendo-ir.com
Company: Gene Gephart Phone: +1-737-414-9213 (US) Email:
investorrelations@heartsciences.com
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Apr 2023 to Apr 2024